September 20, 2019

Shaw and Partners Research Update September 19, 2019: “Fujifilm Takes Up its GvHD License Option Providing Commercial Validation of CYP’s Platform”; ‘Buy’ Rating; Price Target $3.00”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

September 13, 2019

Trading Halt

View Report

July 01, 2019

Shaw and Partners Research Update: “A Key Strategic Position in the Emerging Stem Cell Therapeutic Market; ‘Buy’ Rating; Price Target $2.50”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

May 23, 2019

Shaw and Partners Research Update: “Management and Board Additions Indicate Confidence; ‘Buy’ Rating; Price Target $2.50

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

March 28, 2019

Shaw and Partners Research Update: “Extension of Option Delivers Buying Opportunity; ‘Buy’ Rating; Price Target $2.50”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics